SCHEMBL697564

SCHEMBL697564

OCc1ccc(F)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C19 P33261 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 2/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 1/20 0.43
MAPK1 P28482 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.42
ALOX15 P16050 2/20 0.42
HSD17B10 Q99714 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
CRHBP P24387 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30303054 1.00 ALDH1A1 (0.43) ALDH1A1CYP1A2CYP2C19MEN1KMT2A
SCHEMBL2773091 0.84 RPS6KA3 (0.41) SMN1; SMN2MAPK14
SCHEMBL29673153 0.83 ALDH1A1 (0.41) ALDH1A1CYP1A2CYP2C19MEN1KMT2A
SCHEMBL4098463 0.83 ALDH1A1 (0.41) ALDH1A1CYP1A2CYP2C19MEN1KMT2A
SCHEMBL29857805 0.82 HTR2A (0.39) ALDH1A1CYP1A2CYP2C19MEN1KMT2A
SCHEMBL810490 0.82 HTR2A (0.39) ALDH1A1CYP1A2CYP2C19MEN1KMT2A
SCHEMBL27565478 0.79 CA2 (0.42) ALDH1A1CYP1A2CYP2C19MEN1KMT2A
SCHEMBL531667 0.79 ALDH1A1 (0.43) ALDH1A1CYP1A2CYP2C19MEN1KMT2A
SCHEMBL8290760 0.79 ALDH1A1 (0.42) ALDH1A1CYP1A2CYP2C19MEN1KMT2A
SCHEMBL31085527 0.78 IDO1 (0.40) ALDH1A1CYP1A2KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170001968-A1 AMINOTRIAZOLE- AND AMINOTETRAZOLE-BASED KDM1A INHIBITORS AS EPIGENETIC MODULATORS MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2017-01-05 US claimed
EP-3102034-A1 AMINOTRIAZOLE- AND AMINOTETRAZOLE-BASED KDM1A INHIBITORS AS EPIGENETIC MODULATORS MUSC Foundation For Research Development (US) 2016-12-14 EP claimed
WO-2015120281-A1 AMINOTRIAZOLE- AND AMINOTETRAZOLE-BASED KDM1A INHIBITORS AS EPIGENETIC MODULATORS MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2015-08-13 WO claimed
EP-4748839-A1 POLYCYCLIC COMPOUND AND USE THEREOF CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2026-05-27 EP disclosed
EP-4676926-A1 BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS ThirtyFiveBio Limited (GB) 2026-01-14 EP disclosed
US-20250388615-A9 SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS ARDELYX, INC. (US) 2025-12-25 US disclosed
US-20250214976-A1 GPR35 MODULATORS AND USES THEREOF CROSSIGNAL THERAPEUTICS, INC. 2025-07-03 US disclosed
US-20250136584-A1 Benzimidazole Or Azabenzimidazole Compound, Preparation Method Therefor And Use Thereof CHENGDU DI'AO JIUHONG PHARMACEUTICAL FACTORY (CN) 2025-05-01 US disclosed
US-20250066410-A1 SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS ARDELYX, INC. (US) 2025-02-27 US disclosed
CN-119137105-A GPR35 modulators and uses thereof 交信医药研发公司 2024-12-13 CN disclosed
EP-4467538-A1 BENZIMIDAZOLE OR AZABENZIMIDAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Chengdu Di'Ao Jiuhong Pharmaceutical Factory (CN) 2024-11-27 EP disclosed
EP-0995742-A1 SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-26 EP disclosed
EP-0882720-A1 METHODS FOR MODIFYING 1,3,5-TRIAZINE DERIVATIVES NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) 1998-12-09 EP disclosed
US-5792867-A Method of alkylating of triazine derivatives NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1998-08-11 US disclosed
EP-0760369-A1 PROCESS FOR ALKYLATING TRIAZINE DERIVATIVE NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) 1997-03-05 EP disclosed
EP-0711760-A1 METHOD OF ALKYLATING TRIAZINE DERIVATIVE NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) 1996-05-15 EP disclosed
EP-0212428-B1 DIHYDROBENZO/B /THIOPHENES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS ANTIFUNGALS SCHERING CORPORATION (US) 1990-06-06 EP disclosed
US-4731364-A Dihydrobenzo(B)thiophenes and pharmaceutical compositions thereof useful as antifungals SCHERING CORPORATION (US) 1988-03-15 US disclosed
EP-0212428-A1 Dihydrobenzo/b /thiophenes and pharmaceutical compositions thereof useful as antifungals SCHERING CORPORATION (US) 1987-03-04 EP disclosed
EP-0060617-A1 Fluorobenzyl cyclopropane carboxylates, their preparation, compositions and use as insecticides IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1982-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066410-A1 SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS GPR119, GIPR, GLP1R ALDH1A1 4357/4885CYP1A2 1241/4885CYP2C19 795/4885
US-20170001968-A1 AMINOTRIAZOLE- AND AMINOTETRAZOLE-BASED KDM1A INHIBITORS AS EPIGENETIC MODULATORS KDM1A, KDM1B, KDM3A ALDH1A1 198/4885CYP1A2 227/4885CYP2C19 476/4885
US-20250388615-A9 SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS GPR119, GIPR, FFAR3 ALDH1A1 3776/4885CYP1A2 1343/4885CYP2C19 1106/4885
US-20250214976-A1 GPR35 MODULATORS AND USES THEREOF GPR35, GPR34, GPR68 ALDH1A1 2672/4885CYP1A2 3542/4885CYP2C19 3760/4885
US-20250136584-A1 Benzimidazole Or Azabenzimidazole Compound, Preparation Method Therefor And Use Thereof GLP1R, GIPR, SLC5A1 ALDH1A1 608/4885CYP1A2 1798/4885CYP2C19 981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.